Time to relapse after short- or long-term treatment of severe premenstrual syndrome with sertraline

Archives of General Psychiatry

Volumn 66, Issue 5, 2009, Pages 537-544

  Freeman, Ellen W ^a,b   Rickels, Karl ^a   Sammel, Mary D ^a   Lin, Hui ^a   Sondheimer, Steven J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SERTRALINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; APPETITE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; LIBIDO DISORDER; LONG TERM CARE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; NAUSEA; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADOLESCENT; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; DRUG COST; DRUG EFFECT; ECONOMICS; FOLLOW UP; LUTEAL PHASE; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; RECURRENT DISEASE;

ADOLESCENT; ADULT; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONG-TERM CARE; LUTEAL PHASE; PREMENSTRUAL SYNDROME; QUESTIONNAIRES; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; YOUNG ADULT;

EID: 65549086030     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2008.547     Document Type: Article

References (22)

1. Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology. 2003;28(suppl 3):1-23.
2. Dean BB, Borenstein JE. A prospective assessment investigating the relationship between work productivity and impairment with premenstrual syndrome. JOc- cup Environ Med. 2004;46(7):649-656.
3. Freeman EW. Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder. CNSDrugs. 2004;18(7):453-468.
4. Wyatt KM, Dimmock PW, O'Brien PM. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2002;(4):CD001396.
5. Freeman EW, Sondheimer SJ, Rickels K, Martin PG. A pilot naturalistic follow-up of extended sertraline treatment for severe premenstrual syndrome. J Clin Psychopharmacol. 2004;24(3):351-353.
6. Yonkers KA, Barnett LK, CarmodyT, Rush AJ. Serial discontinuation of SSRI treatment for PMDD. Biol Psychiatry. 1998;43(8 suppl):1S-133S.
7. Pearlstein TB, Stone AB. Long-term fluoxetine treatment of late luteal phase dysphoric disorder. J Clin Psychiatry. 1994;55(8):332-335.
8. Elks ML. Open trial of fluoxetine therapy for premenstrual syndrome. South Med J. 1993;86(5):503-507.
9. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IVAxis 1 Disorders: Patient Edition (SCID-1/P, version2.0). NewYork: New York State Psychiatric Institute; 1995.
10. Freeman EW, DeRubeis RJ, Rickels K. Reliability and validity of a daily diary for premenstrual syndrome. Psychiatry Res. 1996;65(2):97-106.
11. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. IntJ Psychiatry Med. 1997;27(2):93-105.
12. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dys- phoric disorder: a randomized controlled trial. Arch Gen Psychiatry. 1999;56 (10):932-939.
13. Cohen S, KamarckT, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24(4):385-396.
14. Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45(8):742-747.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc. 1958;53(282):457-481. doi:10.2307/2281868.
16. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50(3):163-170.
17. Cox DR. Regression models and life-tables. JRStatSocSeriesB. 1972;34(2): 187-220.
18. McGrath PJ, Stewart JW, Quitkin FM, Chen Y, Alpert JE, Nierenberg AA, FavaM, Cheng J, Petkova E. Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry. 2006;163(9):1542-1548.
19. Zimmerman M, Thongy T. How often do SSRIs and other new-generation antidepressants lose theireffect during continuation treatment? evidence suggesting the rate of true tachyphylaxis during continuation treatment is low. J Clin Psychiatry. 2007;68(8):1271-1276.
20. Quitkin FM, Stewart JW, McGrath PJ, Nunes E, Ocepek-Welikson K, Tricamo E, Rabkin JG, Ross D, Klein DF. Loss of drug effects during continuation therapy. Am J Psychiatry. 1993;150(4):562-565.
21. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25(6):1171-1180.
22. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Ku- novac JL, Leon AC, MuellerTI, Rice JA, Keller MB. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50(2-3):97-108.